Combinations

Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (C) and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

• the Compound (C) has the structure:
• and
• wherein:
• X1, Y1 and Z1 are each independently C or N;
• with the first proviso that at least one of X1, Y1 and Z1 is N;
• with the second proviso that each of X1, Y1 and Z1 is uncharged;
• with third proviso that two of the dotted lines indicate double bonds;
• with the fourth proviso that the valencies of X1, Y1 and Z1 can be each independently satisfied by attachment to a substituent selected from H and R12;
• X2 is O;
• A1 is selected from the group consisting of an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;
• R1 is selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted cycloalkenyl(C1-6 alkyl), an optionally substituted aryl(C1-6 alkyl), an optionally substituted heteroaryl(C1-6 alkyl) and an optionally substituted heterocyclyl(C1-6 alkyl);
• R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl;
• or R2 and R3 together with the carbon to which R2 and R3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
• R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl;
• or R4 and R5 together with the carbon to which R4 and R5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
• R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
• R10 is hydrogen, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
• R11is hydrogen;
• and
• R12 is hydrogen, halogen, an optionally substituted C1-3 alkyl, an optionally substituted C1-3 haloalkyl or an optionally substituted C1-3 alkoxy;
• and
• the one or more of Compound (B) has the structure
• wherein:
• R1a is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl, a substituted or unsubstituted C3-C6 cycloalkyl, a substituted or unsubstituted C1-C6 alkoxy, an unsubstituted mono-C1-C6 alkylamine and an unsubstituted di-C1-C6 alkylamine;
• each R2a is independently selected from the group consisting of halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl;
• or
• when m-a is 2 or 3, each R2a is independently selected from the group consisting of halogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl, or two R2a groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C3-C6 cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;
• R4a is selected from the group consisting of NO2, S(O)R6a, SO2R6a, halogen, cyano and an unsubstituted C1-C6 haloalkyl;
• R5a is—X1a-(Alk1a)n R7a;
• Alk1a is selected from an unsubstituted C1-C4 alkylene and a C1-C4 alkylene substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, an unsubstituted C1-C3 alkyl and an unsubstituted C1-C3 haloalkyl;
• R6a is selected from the group consisting of a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 haloalkyl and a substituted or unsubstituted C3-C6 cycloalkyl;
• R7a is selected from a substituted or unsubstituted C1-C6 alkoxy, a substituted or unsubstituted C3-C10 cycloalkyl, a substituted or unsubstituted 3 to 10 membered heterocyclyl, hydroxy, amino, a substituted or unsubstituted mono-substituted amine group, a substituted or unsubstituted di-substituted amine group, a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido;
• m-a is 0, 1, 2 or 3;
• n-a is selected from the group consisting of 0 and 1;
• X1a is selected from the group consisting of —O—, —S— and —NH—;
• and
• provided that the Compound (C) cannot be
• or a pharmaceutically acceptable salt thereof.